8 August 2005 in Journal of Cellular Biochemistry
This article focuses on recent findings that the type V TGF‐β receptor (TβR‐V), which co‐expresses with other TGF‐β receptors (TβR‐I, TβR‐II, and TβR‐III) in all normal cell types studied, is involved in growth inhibition by IGFBP‐3 and TGF‐β and that TGF‐β activity is regulated by two distinct endocytic pathways (clathrin‐ and caveolar/lipid‐raft‐mediated). TGF‐β is a potent growth inhibitor for most cell types, including epithelial and endothelial cells. The signaling by which TGF‐β controls cell proliferation is not well understood. Many lines of evidence indicate that other signaling pathways, in addition to the prominent TβR‐I/TβR‐II/Smad2/3/4 signaling cascade, are required for mediating TGF‐β‐induced growth inhibition. Recent studies revealed that TβR‐V, which is identical to LRP‐1, mediates IGF‐independent growth inhibition by IGFBP‐3 and mediates TGF‐β‐induced growth inhibition in concert with TβR‐I and TβR‐II. In addition, IRS proteins and a Ser/Thr‐specific protein phosphatase(s) are involved in the TβR‐V‐mediated growth inhibitory signaling cascade. The TβR‐V signaling cascade appears to cross‐talk with the TβR‐I/TβR‐II, insulin receptor (IR), IGF‐I receptor (IGF‐IR), integrin and c‐Met signaling cascades. Attenuation or loss of the TβR‐V signaling cascade may enable carcinoma cells to escape from TGF‐β growth control and may contribute to the aggressiveness and invasiveness of these cells via promoting epithelial‐to‐mesenchymal transdifferentiation (EMT). Finally, the ratio of TGF‐β binding to TβR‐II and TβR‐I is a signal controlling TGF‐β partitioning between two distinct endocytosis pathways and resultant TGF‐β responsiveness. These recent studies have provided new insights into the molecular mechanisms underlying TGF‐β‐induced cellular growth inhibition, cross‐talk between the TβR‐V and other signaling cascades, the signal that controls TGF‐β responsiveness and the role of TβR‐V in tumorigenesis.
1 June 2009 in Journal of Cell Science
Clathrin-dependent endocytosis is believed to be involved in TGFβ-stimulated cellular responses, but the subcellular locus at which TGFβ induces signaling remains unclear. Here, we demonstrate that inhibitors of clathrin-dependent endocytosis, which are known to arrest the progression of endocytosis at coated-pit stages, inhibit internalization of cell-surface-bound TGFβ and promote colocalization and accumulation of TβR-I and SARA at the plasma membrane. These inhibitors enhance TGFβ-induced signaling and cellular responses (Smad2 phosphorylation/nuclear localization and expression of PAI-1). Dynasore, a newly identified inhibitor of dynamin GTPase activity, is one of the most potent inhibitors among those tested and, furthermore, is a potent enhancer of TGFβ. Dynasore ameliorates atherosclerosis in the aortic endothelium of hypercholesterolemic ApoE-null mice by counteracting the suppressed TGFβ responsiveness caused by the hypercholesterolemia, presumably acting through its effect on TGFβ endocytosis and signaling in vascular cells.
21 June 2002 in The FASEB Journal
Wound healing consists of re‐epithelialization, contraction and formation of granulation and scar tissue. TGF‐β is involved in these events, but its exact roles are not well understood. Here we demonstrate that topical application of a synthetic TGF‐β antagonist accelerates re‐epithelialization in pig burn wounds (100% re‐epithelialization in antagonist‐treated wounds vs. ~ 70% reepithelialization in control wounds on postburn day 26) and reduces wound contraction and scarring in standard pig skin burn, pig skin excision and rabbit skin excision wounds. These results support the distinct roles of TGF‐β in the complex process of wound healing and demonstrate the feasibility of manipulating wound healing by TGF‐β antagonist.
15 October 2007 in Journal of Cell Science
Hypercholesterolemia is a major causative factor for atherosclerotic cardiovascular disease. The molecular mechanisms by which cholesterol initiates and facilitates the process of atherosclerosis are not well understood. Here, we demonstrate that cholesterol treatment suppresses or attenuates TGF-β responsiveness in all cell types studied as determined by measuring TGF-β-induced Smad2 phosphorylation and nuclear translocation, TGF-β-induced PAI-1 expression, TGF-β-induced luciferase reporter gene expression and TGF-β-induced growth inhibition. Cholesterol, alone or complexed in lipoproteins (LDL, VLDL), suppresses TGF-β responsiveness by increasing lipid raft and/or caveolae accumulation of TGF-β receptors and facilitating rapid degradation of TGF-β and thus suppressing TGF-β-induced signaling. Conversely, cholesterol-lowering agents (fluvastatin and lovastatin) and cholesterol-depleting agents (β-cyclodextrin and nystatin) enhance TGF-β responsiveness by increasing non-lipid raft microdomain accumulation of TGF-β receptors and facilitating TGF-β-induced signaling. Furthermore, the effects of cholesterol on the cultured cells are also found in the aortic endothelium of ApoE-null mice fed a high-cholesterol diet. These results suggest that high cholesterol contributes to atherogenesis, at least in part, by suppressing TGF-β responsiveness in vascular cells.
30 October 2007 in Journal of Cellular Physiology
20 October 2006 in FEBS Letters